CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidKinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Forma y color:Odour SolidCdk2/Cyclin Inhibitory Peptide II
CAS:<p>Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].</p>Fórmula:C110H200N48O25Forma y color:SolidPeso molecular:2595.07CDK8-IN-12
CAS:<p>CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.</p>Fórmula:C21H20ClN3O2Pureza:99.46% - 99.83%Forma y color:SoildPeso molecular:381.86CDK2/PIM1-IN-1
<p>CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.</p>Forma y color:Odour SolidPROTAC CDK9 degrader-7
CAS:<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Fórmula:C43H50Cl2N8O9Forma y color:SoildPeso molecular:893.81Roccellic Acid
CAS:<p>Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.</p>Fórmula:C17H32O4Forma y color:SolidPeso molecular:300.43PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Fórmula:C43H51FN12O7Forma y color:SolidPeso molecular:866.94CDK12-IN-6
CAS:<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Fórmula:C20H21F2N9Forma y color:SolidPeso molecular:425.448Cdk2/Cyclin Inhibitory Peptide I
<p>CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.</p>Fórmula:C111H196N48O23Pureza:98%Forma y color:SolidPeso molecular:2571.05NecroIr1
<p>NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.</p>Fórmula:C40H29ClIrN5OForma y color:SolidPeso molecular:823.36PROTAC CDK9 degrader-5
CAS:<p>PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.</p>Fórmula:C42H48Cl2N8O9Pureza:98%Forma y color:SolidPeso molecular:879.78SNX7
CAS:<p>SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.</p>Fórmula:C15H14N2OPureza:99.05%Forma y color:SolidPeso molecular:238.28CPS2
CAS:<p>CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.</p>Fórmula:C38H42N12O10S2Forma y color:SolidPeso molecular:890.94CDK7-IN-5
CAS:<p>CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).</p>Fórmula:C34H45N9O2Forma y color:SolidPeso molecular:611.795PROTAC CDK9 degrader-2
CAS:<p>PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.</p>Fórmula:C39H36N6O10Pureza:98%Forma y color:SolidPeso molecular:748.74BSJ-03-204
CAS:<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Fórmula:C43H48N10O8Forma y color:SolidPeso molecular:832.9TMX-2138
CAS:<p>TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.</p>Fórmula:C40H43BrFN9O11SForma y color:SolidPeso molecular:956.791EGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Fórmula:C24H16N6OS2Pureza:98%Forma y color:SolidPeso molecular:468.55JH-XI-10-02
CAS:<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Fórmula:C53H69N5O9Pureza:98%Forma y color:SolidPeso molecular:920.161
